by In this post, you will learn how Lenacapavir Injection prevents HIV, how effective it is, dosing, common side effects, who may be eligible, and where it is currently available.
What Is Lenacapavir Injection for HIV Prevention?
Lenacapavir is a long-acting HIV prevention medicine used as pre-exposure prophylaxis (PrEP). In the United States, the PrEP formulation is marketed as Yeztugo. Unlike daily oral PrEP, lenacapavir is administered by a healthcare professional as a subcutaneous injection every six months after the initial dosing schedule.
The U.S. Food and Drug Administration (FDA) approved Yeztugo to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg who are at risk of HIV acquisition. WHO also recommends twice-yearly injectable lenacapavir as an additional HIV prevention choice.
It is important to understand that lenacapavir for PrEP is intended to prevent HIV in people who do not have HIV. It is not a cure for HIV and should not be used alone to treat an existing HIV infection.
How Does Lenacapavir Work?
Lenacapavir belongs to a newer class of antiretroviral medicines called HIV-1 capsid inhibitors.
The capsid is the protein shell surrounding HIV’s genetic material. Lenacapavir interferes with the capsid and disrupts important stages of the HIV life cycle. This helps prevent HIV from successfully establishing an infection.
One of the major advantages is its long-acting formulation. Instead of relying on taking a PrEP pill every day, people using the injectable formulation return to a healthcare provider for their scheduled injections approximately every six months.
That dosing schedule may be particularly useful for people who find daily medication difficult because of busy schedules, stigma, privacy concerns, or challenges remembering a pill.
How Effective Is Lenacapavir for HIV Prevention?
Clinical trials have shown very high protection against sexually acquired HIV-1.
In PURPOSE 1, which studied adolescent girls and young women in South Africa and Uganda, there were zero HIV infections among 2,134 participants who received lenacapavir, compared with 16 infections among 1,068 participants receiving daily oral Truvada. The FDA reported a 100% reduction in the risk of incident HIV infection compared with Truvada in that trial.
In PURPOSE 2, which included cisgender men, transgender women, transgender men and gender-nonbinary participants at risk of HIV acquisition, two HIV infections occurred among 2,179 people receiving lenacapavir compared with nine among 1,086 people receiving Truvada. The FDA reported an 89% reduction in risk compared with Truvada in that trial.
These results are impressive, but it is important not to interpret them as meaning that HIV prevention is guaranteed. The FDA labeling states that Yeztugo is not always effective and emphasizes adherence to the dosing schedule and regular HIV testing.
How Often Is Lenacapavir Injection Given?
The current U.S. Yeztugo schedule involves an initial combination of injections and oral tablets, followed by injections every six months.
According to the FDA-approved prescribing information:
- Day 1: Two subcutaneous injections plus two oral tablets.
- Day 2: Two oral tablets.
- Every 6 months: Two subcutaneous injections for continuation.
- HIV testing is required before starting and before subsequent injections.
The injections are administered by a healthcare professional, generally into the abdomen; the thigh may be used as an alternative site.
Because the medicine remains in the body for a prolonged period, keeping appointments is especially important.
Who Can Use Lenacapavir for HIV PrEP?
Eligibility depends on local regulatory guidance and an individual’s health circumstances.
Under the current U.S. FDA indication, Yeztugo is approved for adults and adolescents weighing at least 35 kg who are at risk of acquiring HIV-1 through sex. The person must have a confirmed negative HIV-1 status before starting PrEP.
A healthcare professional should assess whether injectable lenacapavir is appropriate. HIV testing is particularly important because using lenacapavir alone in someone who already has HIV can contribute to the development of drug resistance.
Why Is HIV Testing So Important Before Lenacapavir?
Lenacapavir for PrEP is not a complete HIV treatment regimen.
If someone has an undiagnosed HIV infection and receives lenacapavir alone, HIV can potentially develop resistance to the medicine. For this reason, the FDA requires HIV testing before initiation and before subsequent injections, with additional testing when clinically appropriate.
People should also tell their healthcare provider if they develop symptoms that could indicate a recent HIV infection, such as fever, fatigue, muscle or joint aches, rash, sore throat, night sweats, vomiting or swollen lymph nodes.
What Are the Side Effects of Lenacapavir Injection?
The most common side effects reported with Yeztugo are:
- Injection-site reactions
- Headache
- Nausea
Injection-site reactions can include a lump or nodule, pain, swelling, redness, itching, bruising, warmth or hardening of the skin. Because lenacapavir forms a drug depot under the skin, a lump can sometimes remain for longer than other injection-site reactions.
Most people considering lenacapavir should discuss the potential benefits and risks with a qualified healthcare professional, particularly if they take other prescription medicines, over-the-counter drugs or herbal supplements.
What Happens If You Miss a Lenacapavir Injection?
The six-month schedule is an important part of effective HIV prevention.
If an injection is expected to be delayed by more than two weeks, the FDA labeling provides for temporary oral lenacapavir dosing while the person arranges to resume injections. Missing injections without appropriate alternative PrEP can increase the risk of HIV infection.
If someone decides to stop lenacapavir altogether, they should speak with a healthcare provider about another HIV prevention option. This is important because lenacapavir can remain in the body for 12 months or longer after the last injection, while drug levels gradually decline.
Does Lenacapavir Prevent Other STIs?
No.
Lenacapavir is designed to reduce the risk of HIV-1 acquisition. It does not protect against sexually transmitted infections such as gonorrhea, chlamydia or syphilis.
Condoms, STI testing and other appropriate prevention measures can still be important parts of a comprehensive sexual-health strategy.
Lenacapavir Availability Around the World
Availability is changing rapidly as countries introduce long-acting HIV prevention.
WHO recommended injectable lenacapavir as an additional HIV prevention option in July 2025. By July 2026, WHO reported that lenacapavir was being introduced in 10 countries, with rollout planned in a further 14 countries.
Availability, eligibility, product names, dosing protocols and access arrangements can differ by country. Therefore, people should check with their national HIV program, public-health service, clinic or healthcare provider rather than assuming that the medicine is available at every pharmacy or HIV clinic.
Lenacapavir Availability in Nigeria
Nigeria is among the countries beginning implementation of long-acting lenacapavir for HIV prevention. WHO reported that Nigeria formally introduced lenacapavir in March 2026, with the initial phase of implementation beginning through the country’s HIV prevention program and with support from national and international partners.
For people in Nigeria, access may depend on the location and phase of the national rollout. A healthcare provider or participating HIV prevention service can provide the most current information about eligibility and where the medication is being offered.
Lenacapavir vs Daily Oral PrEP
The biggest difference is how often the medicine is administered.
| Feature | Lenacapavir PrEP | Daily oral PrEP |
|---|---|---|
| Administration | Injection by healthcare provider | Tablet |
| Schedule | Every 6 months after initiation | Usually daily |
| HIV testing | Required as part of ongoing care | Required as part of PrEP care |
| STI protection | No | No |
| Adherence challenge | Keeping injection appointments | Remembering regular doses |
| Injection-site reactions | Possible | Not applicable |
Neither option is automatically the best choice for everyone. The right PrEP method depends on medical history, preferences, access, lifestyle and the recommendations of a healthcare professional.
Is Lenacapavir a Cure for HIV?
No.
This distinction is important because lenacapavir is also used under the brand name Sunlenca as part of combination treatment for certain adults with multidrug-resistant HIV-1. The prevention product, Yeztugo, is used as PrEP in people who are HIV-negative.
If a person tests positive for HIV while receiving PrEP, they need to be evaluated promptly and transitioned to a complete HIV treatment regimen.
Frequently Asked Questions
Is lenacapavir injection given every six months?
Yes. After the initial dosing regimen, the current U.S. Yeztugo schedule calls for two subcutaneous injections every 26 weeks, with a two-week scheduling window.
Is lenacapavir 100% effective?
Clinical trials demonstrated extremely high efficacy. PURPOSE 1 recorded zero HIV infections in the lenacapavir group, while PURPOSE 2 recorded two infections among 2,179 participants. However, no prevention method should be described as guaranteeing protection, and adherence to the prescribed schedule and HIV testing remains important.
Does lenacapavir replace condoms?
No. Lenacapavir is intended to prevent HIV-1 and does not prevent other STIs. Condoms and STI testing can provide additional protection.
Can someone with HIV use lenacapavir for PrEP?
No. Yeztugo PrEP is intended for people who are confirmed HIV-negative. People with HIV need a complete HIV treatment regimen prescribed by a healthcare professional.
How long does lenacapavir stay in the body?
The FDA labeling states that residual concentrations can remain in systemic circulation for 12 months or longer after an injection. This long-lasting effect is one reason why follow-up and planning for alternative PrEP are important if injections are discontinued.
Bottom Line
Lenacapavir injection for HIV prevention is a major development in PrEP because it offers protection with a twice-yearly injection schedule rather than relying on daily pills. Clinical trials have demonstrated very high effectiveness, while WHO now recommends injectable lenacapavir as an additional HIV prevention choice.
However, it is not a cure for HIV, does not prevent other STIs, and requires regular HIV testing and adherence to the injection schedule. Because availability and national guidelines are evolving, anyone considering lenacapavir should speak with a qualified healthcare provider or an authorized HIV prevention service.
Medical note: This article is for general education and information purposes and should not replace individualized medical advice, HIV testing, or care from a qualified healthcare professional. Regulatory approvals and availability can change, so readers should verify current local guidance.
